2018 annual results
- Growth and EBITDA in line with announced targets
› Reported revenue: €789.6 million
› Revenue at constant exchange rates: €825.7 million; +2.3%, in line with the guidance given at Capital Markets Day in April 2018 (GEAR 2023 plan)
› Reported EBITDA: €110.6 million, also in line with the guidance
- Successful implementation of the GEAR 2023 strategic plan
› Organic growth: transition to direct distribution in Japan in October, new indications for Lipiodol®, entry into phase III for gadopiclenol
› External growth: strengthening of the Interventional Imaging offering with two initial acquisitions and identification of new targets
- 2019, further transformation
› Gradual establishment of industrial synergies
› Start of sales of Accurate Medical Therapeutics microcatheters in the United States and then in Europe
› Opportunities for growth in Interventional Imaging
Villepinte, March 26, 2019 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its consolidated annual results for 2018.
On March 26, 2019, the Board of Directors approved the financial statements for the period ended December 31, 2018. The audit procedures have been completed, and the statutory auditors’ report is being prepared.
Main highlights of the 2018 financial year
› February: acquisition of the Israeli company Accurate Medical Therapeutics, specialising in the development of microcatheters for Interventional Imaging
› April: presentation of the GEAR 2023 strategic plan, which aims to accelerate organic growth and generate external growth through acquisitions, particularly in the field of Interventional Imaging;
› April: acquisition of a new microsphere technology from Occlugel to strengthen the Intervention Imaging offering;
› June: a strategic partnership signed with IBM Watson Health for joint development and marketing of artificial intelligence solutions for earlier, more accurate diagnosis and therapeutic decision-making support for liver tumours;
› October: launch of direct distribution in Japan, the world’s number 2 market;
› An extension of indications obtained in numerous countries for Lipiodol Ultra-Fluid® in Interventional Imaging for chemo-embolization of liver tumours by microcatheter;
› Further development of NCE gadopiclenol for MRI. Preclinical studies have demonstrated the efficacy and safety of use of this product, and its development will proceed to phase III starting in early 2019.
Activity marked by a significant exchange rate effect
The reported revenue of €789.6 million, down 2.2%, was affected by an unfavourable exchange rate effect of €36.1 million. The main exchange rate impacts came mainly from the Brazilian real (€10.6 million), the US dollar (€7.6 million), the Turkish lira (€5.5 million), and the Argentine peso (€3.1 million).
At constant exchange rates, revenue totalled €825.7 million, representing 2.3% in fully organic growth. Diagnostic Imaging revenue at constant exchange rates decreased slightly to €722.6 million (-0.7%) compared with the 2017 financial year. The Imaging Intervention activity confirmed its strong growth with revenue at constant exchange rates at €67.2 million, up 18.6%.
EBITDA on track
Reported EBITDA totals €110.6 million. For the first time, it incorporates the full-year impact of the arrival of the Dotarem® generic in Europe. It also reflects the efforts made under the GEAR 2023 plan with the switch to a direct distribution organisation in Japan, stronger positioning in countries with high commercial potential, and the costs associated with the transition to phase III for gadopiclenol, Dotarem’s successor.
Operating Income totalled €69.9 million, or 8.9% of revenue.
Net income was stable at €46.8 million compared with €46.2 million in 2017. This figure incorporates a favourable change in the effective tax rate to 29.5%.
Sound financial position, refinancing of the Group’s debt
The Group enjoys solid fundamentals. Equity increased by €24.6 million to €366.8 million, and net debt amounts to €308.7 million. With €98.8 million in cash flow, Guerbet has a solid financial position with leverage (Net Debt/EBITDA) of 2.79.
The Board of Directors will propose a dividend of €0.85 per share to the shareholders at the General Meeting on May 24, 2019.
In order to contribute to the Group’s development as part of its GEAR 2023 strategic plan, and in view of its debt capacity, Guerbet signed a five-year €500 million credit agreement on February 13, 2019, to refinance its existing debt.
This contract was entered into with nine financial partners, coordinated by BNP Paribas.
This new debt has a single covenant (net debt/EBITDA = 4.0) over the life of the loan.
Executive Committee strengthening
As part of its GEAR 2023 growth strategy, the Group has decided to appoint Jean-François Le Martret as Deputy CEO with two specific missions: M&A operations and deployment of the « Cost to Win » project. The Group will welcome a new CFO, Jérôme Estampes from 1 April. He has spent most of his career in international cosmetics companies (Crown, Coty, Pat McGrath).
In 2019, the Group anticipates a moderate sales growth. Dotarem will continue to benefit from higher volumes and from the switch to direct distribution in Japan but will be impacted by a continued price decrease and by the arrival of generics in new countries. Guerbet also has development drivers in Interventional Imaging and digital solutions. In 2019, the start of sales of the Accurate Medical Therapeutics DraKon® and SeQure® microcatheters in the US, and then in Europe once the CE marking is obtained, is a growth area in Guerbet’s strategy. In addition, the Group should benefit from the full-year contribution of Lipiodol’s indications registered in new countries in 2018.
The financial position for the current year should benefit from a significant improvement in cash flow with a positive change in the WCR, particularly through the decrease in inventories.
At constant exchange rates: amounts and rates of growth are calculated by cancelling out the exchange rate effect, which is defined as the difference between the indicator’s value for period N, converted at the exchange rate for period N-1, and the indicator’s value for period N-1.
Publication of first-quarter 2019 revenue
April 18, 2019, after trading